The role of TMEM26 in disrupting tight junctions and activating NF-κB signaling to promote epithelial-mesenchymal transition in esophageal squamous cell carcinoma

Han, Guohu; Zhou, Shuangshuang; Shen, Junjun; Yang, Yuanyuan; Bian, Xuyu; Li, Yahu; Ling, Rui; Liang, Rongrui; Tao, Min

doi:10.1016/j.clinsp.2023.100276

Cited by 1 publication

(1 citation statement)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In terms of cell proliferation and death, NF-κB participates in the expression of cell cycle regulators, including cyclin A, cyclin D1, and CDK6, and the activation of NF-κB can protect cells from TNF-α-induced apoptosis [32]. During cancer development, uncontrolled proliferation and insensitivity to cell death are often accompanied by the activation of NF-κB signaling [33], this is reflected in a variety of cancers, including breast cancer [34], prostate cancer [35], esophageal squamous cell carcinoma [36], lymphoma [37], lung adenocarcinoma [38], etc. Abnormal NF-κB signaling also frequently leads to abnormal changes in tumor resistance, local inflammatory response, and immune microenvironment [38][39][40][41].…”

Section: Discussionmentioning

confidence: 99%

Role of NF-κB pathway in kidney renal clear cell carcinoma and its potential therapeutic implications

Sun,

Chen,

2023

Aging

View full text Add to dashboard Cite

Kidney renal clear cell carcinoma (KIRC), a common malignant tumor of the urinary system, is the most aggressive renal tumor subtype. Since the discovery of nuclear factor kappa B (NF-κB) in 1986, many studies have demonstrated abnormal NF-κB signaling is associated with the development of various cancers, including kidney renal clear cell carcinoma. In this study, the relationship between NF-κB and kidney renal clear cell carcinoma was confirmed using bioinformatics analysis. First, we explored the differential expression of copy number variation (CNV), single nucleotide variant (SNV), and messenger RNA (mRNA) in NF-κB-related genes in different types of cancer, as well as the impact on cancer prognosis and sensitivity to common chemotherapy drugs. Then, we divided the mRNA expression levels of NF-κB-related genes in KIRC patients into three groups through GSVA cluster analysis and explored the correlation between the NF-κB pathway and clinical data of KIRC patients, classical cancer-related genes, common anticancer drug responsiveness, and immune cell infiltration. Finally, 11 tumor-related genes were screened using least absolute shrinkage and selection operator (LASSO) regression to construct a prognostic model. In addition, we used the UALCAN and HPA databases to verify the protein levels of three key NF-κB-related genes ( CHUK, IKGGB, and IKBKG ) in KIRC. In conclusion, our study established a prognostic survival model based on NF-κB-related genes, which can be used to predict the prognosis of patients with KIRC.

show abstract